Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Virology Journal
Published in: Virology Journal 1/2019

Open Access 01-12-2019 | Review

Marburg virus pathogenesis – differences and similarities in humans and animal models

Authors: Kyle Shifflett, Andrea Marzi

Published in: Virology Journal | Issue 1/2019

Login to get access

Abstract

Marburg virus (MARV) is a highly pathogenic virus associated with severe disease and mortality rates as high as 90%. Outbreaks of MARV are sporadic, deadly, and often characterized by a lack of resources and facilities to diagnose and treat patients. There are currently no approved vaccines or treatments, and the chaotic and infrequent nature of outbreaks, among other factors, makes testing new countermeasures during outbreaks ethically and logistically challenging. Without field efficacy studies, researchers must rely on animal models of MARV infection to assess the efficacy of vaccines and treatments, with the limitations being the accuracy of the animal model in recapitulating human pathogenesis. This review will compare various animal models to the available descriptions of human pathogenesis and aims to evaluate their effectiveness in modeling important aspects of Marburg virus disease.
Literature
1.
Languon S, Quaye O. Filovirus Disease Outbreaks: A Chronological Overview. Virology (Auckl). 2019;10:1178122X19849927.
2.
Kuhn JH, Adachi T, Adhikari NKJ, Arribas JR, Bah IE, Bausch DG, et al. New filovirus disease classification and nomenclature. Nat Rev Microbiol. 2019;17(5):261–3.PubMedPubMedCentralCrossRef
3.
Shi M, Lin XD, Chen X, Tian JH, Chen LJ, Li K, et al. The evolutionary history of vertebrate RNA viruses. Nature. 2018;556(7700):197–202.PubMedCrossRef
4.
Feldmann H, Muhlberger E, Randolf A, Will C, Kiley MP, Sanchez A, et al. Marburg virus, a filovirus: messenger RNAs, gene order, and regulatory elements of the replication cycle. Virus Res. 1992;24(1):1–19.PubMedCrossRef
5.
Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. Virus Res. 1995;39(2–3):129–50.PubMedCrossRef
6.
Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, et al. Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae. Arch Virol. 2013;158(1):301–11.PubMedCrossRef
7.
Siegert R, Shu HL, Slenczka W, Peters D, Muller G. On the etiology of an unknown human infection originating from monkeys. Dtsch Med Wochenschr. 1967;92(51):2341–3.PubMedCrossRef
8.
Bausch DG, Nichol ST, Muyembe-Tamfum JJ, Borchert M, Rollin PE, Sleurs H, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N Engl J Med. 2006;355(9):909–19.PubMedCrossRef
9.
Towner JS, Khristova ML, Sealy TK, Vincent MJ, Erickson BR, Bawiec DA, et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol. 2006;80(13):6497–516.PubMedPubMedCentralCrossRef
10.
Pigott DM, Golding N, Mylne A, Huang Z, Weiss DJ, Brady OJ, et al. Mapping the zoonotic niche of Marburg virus disease in Africa. Trans R Soc Trop Med Hyg. 2015;109(6):366–78.PubMedPubMedCentralCrossRef
11.
12.
Bertherat E, Talarmin A, Zeller H. Democratic Republic of the Congo: between civil war and the Marburg virus. Internateional Committee of Technical and Scientific Coordination of the Durba epidemic. Med Trop (Mars). 1999;59(2):201–4.
13.
Centers for Disease C, Prevention. Imported case of Marburg hemorrhagic fever - Colorado, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(49):1377–81.
14.
Timen A, Koopmans MP, Vossen AC, van Doornum GJ, Gunther S, van den Berkmortel F, et al. Response to imported case of Marburg hemorrhagic fever, the Netherland. Emerg Infect Dis. 2009;15(8):1171–5.PubMedPubMedCentralCrossRef
15.
Towner JS, Pourrut X, Albarino CG, Nkogue CN, Bird BH, Grard G, et al. Marburg virus infection detected in a common African bat. PLoS One. 2007;2(8):e764.PubMedPubMedCentralCrossRef
16.
Amman BR, Jones ME, Sealy TK, Uebelhoer LS, Schuh AJ, Bird BH, et al. Oral shedding of Marburg virus in experimentally infected Egyptian fruit bats (Rousettus aegyptiacus). J Wildl Dis. 2015;51(1):113–24.PubMedPubMedCentralCrossRef
17.
Paweska JT, Jansen van Vuren P, Fenton KA, Graves K, Grobbelaar AA, Moolla N, et al. Lack of Marburg Virus Transmission From Experimentally Infected to Susceptible In-Contact Egyptian Fruit Bats. J Infect Dis. 2015;212(Suppl 2):S109–18.PubMedCrossRef
18.
Paweska JT, van Vuren PJ, Masumu J, Leman PA, Grobbelaar AA, Birkhead M, et al. Virological and Serological Findings in Rousettus aegyptiacus Experimentally Inoculated with Vero Cells-Adapted Hogan Strain of Marburg Virus. PLoS One. 2012;7(9).PubMedPubMedCentralCrossRef
19.
20.
21.
22.
Glaze ER, Roy MJ, Dalrymple LW, Lanning LL. A comparison of the pathogenesis of Marburg virus disease in humans and nonhuman Primates and evaluation of the suitability of these animal models for predicting clinical efficacy under the 'Animal Rule'. Comp Med. 2015;65(3):241–59.PubMedPubMedCentral
23.
Gear JS, Cassel GA, Gear AJ, Trappler B, Clausen L, Meyers AM, et al. Outbreak of Marburg virus disease in Johannesburg. Br Med J. 1975;4(5995):489–93.PubMedPubMedCentralCrossRef
24.
Smith DH, Johnson BK, Isaacson M, Swanapoel R, Johnson KM, Killey M, et al. Marburg-virus disease in Kenya. Lancet. 1982;1(8276):816–20.PubMedCrossRef
25.
Martines RB, Ng DL, Greer PW, Rollin PE, Zaki SR. Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. J Pathol. 2015;235(2):153–74.PubMedCrossRef
26.
Roberts A, Kemp C. Ebola and Marburg hemorrhagic fevers. J Am Acad Nurse Pract. 2001;13(7):291–2.PubMedCrossRef
27.
28.
Bechtelsheimer H, Korb G, Gedigk P. The morphology and pathogenesis of "Marburg virus" hepatitis. Hum Pathol. 1972;3(2):255–64.PubMedCrossRef
29.
Stille W, Böhle E. Clinical Course and Prognosis of Marburg Virus (“Green-Monkey”) Disease. In: Martini GA, Siegert R, editors. Marburg Virus Disease. Berlin, Heidelberg: Springer Berlin Heidelberg; 1971. p. 10–8.CrossRef
30.
Havemann K, Schmidt HA. Haematological Findings in Marburg Virus Disease: Evidence for Involvement of the Immunological System. In: Martini GA, Siegert R, editors. Marburg Virus Disease. Berlin, Heidelberg: Springer Berlin Heidelberg; 1971. p. 34–40.CrossRef
31.
Stonier SW, Herbert AS, Kuehne AI, Sobarzo A, Habibulin P, Dahan CVA, et al. Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. J Exp Med. 2017;214(9):2563–72.PubMedPubMedCentralCrossRef
32.
Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by Ebola and Marburg viruses. Lab Investig. 2000;80(2):171–86.PubMedCrossRef
33.
Geisbert TW, Jaax NK. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct Pathol. 1998;22(1):3–17.PubMedCrossRef
34.
Geisbert TW, Strong JE, Feldmann H. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J Infect Dis. 2015;212(Suppl 2):S91–7.PubMedPubMedCentralCrossRef
35.
Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, Young HA, Formenty P, Fritz EA, et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis. 2007;196(Suppl 2):S372–81.PubMedCrossRef
36.
Fernando L, Qiu X, Melito PL, Williams KJ, Feldmann F, Feldmann H, et al. Immune response to Marburg virus Angola infection in nonhuman Primates. J Infect Dis. 2015;212(Suppl 2):S234–41.PubMedCrossRef
37.
Alves DA, Glynn AR, Steele KE, Lackemeyer MG, Garza NL, Buck JG, et al. Aerosol exposure to the Angola strain of Marburg virus causes lethal viral hemorrhagic fever in cynomolgus macaques. Vet Pathol. 2010;47(5):831–51.PubMedCrossRef
38.
Johnston SC, Lin KL, Twenhafel NA, Raymond JL, Shamblin JD, Wollen SE, et al. Dose response of MARV/Angola infection in Cynomolgus macaques following IM or aerosol exposure. PLoS One. 2015;10(9):e0138843.PubMedPubMedCentralCrossRef
39.
MG HR, Experimental Infection of Monkeys with the Marburg Virus. In: SR MGA, editor. Marburg Virus Disease. Berlin, Heidelberg: Springer; 1971.
40.
Lin KL, Twenhafel NA, Connor JH, Cashman KA, Shamblin JD, Donnelly GC, et al. Temporal characterization of Marburg virus Angola infection following aerosol challenge in rhesus macaques. J Virol. 2015;89(19):9875–85.PubMedPubMedCentralCrossRef
41.
Woolsey C, Geisbert JB, Matassov D, Agans KN, Borisevich V, Cross RW, et al. Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates. J Infect Dis. 2018;218(suppl_5):S582–S7.PubMedPubMedCentralCrossRef
42.
Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci Transl Med. 2017;9:384.CrossRef
43.
Dye JM, Warfield KL, Wells JB, Unfer RC, Shulenin S, Vu H, et al. Virus-like particle vaccination protects nonhuman Primates from lethal aerosol exposure with Marburgvirus (VLP vaccination protects macaques against aerosol challenges). Viruses. 2016;8(4):94.PubMedPubMedCentralCrossRef
44.
Hensley LE, Alves DA, Geisbert JB, Fritz EA, Reed C, Larsen T, et al. Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques. J Infect Dis. 2011;204(Suppl 3):S1021–31.PubMedCrossRef
45.
Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of ebola virus. J Virol. 2009;83(14):7296–304.PubMedPubMedCentralCrossRef
46.
Simpson DI, Zlotnik I, Rutter DA. Vervet monkey disease. Experiment infection of Guinea pigs and monkeys with the causative agent. Br J Exp Pathol. 1968;49(5):458–64.PubMedPubMedCentral
47.
48.
Marzi A, Menicucci AR, Engelmann F, Callison J, Horne EJ, Feldmann F, et al. Protection against Marburg virus using a recombinant VSV-vaccine depends on T and B cell activation. Front Immunol. 2018;9:3071.PubMedCrossRef
49.
Furuyama W, Marzi A. Ebola virus: pathogenesis and countermeasure development. Annu Rev Virol. 2019;6(1):435–58.PubMedCrossRef
50.
Carrion R Jr, Ro Y, Hoosien K, Ticer A, Brasky K, de la Garza M, et al. A small nonhuman primate model for filovirus-induced disease. Virology. 2011;420(2):117–24.PubMedCrossRef
51.
Smither SJ, Nelson M, Eastaugh L, Laws TR, Taylor C, Smith SA, et al. Experimental respiratory Marburg virus haemorrhagic fever infection in the common marmoset (Callithrix jacchus). Int J Exp Pathol. 2013;94(2):156–68.PubMedPubMedCentralCrossRef
52.
Bray M. The role of the type I interferon response in the resistance of mice to filovirus infection. J Gen Virol. 2001;82(Pt 6):1365–73.PubMedCrossRef
53.
Raymond J, Bradfute S, Bray M. Filovirus infection of STAT-1 knockout mice. J Infect Dis. 2011;204(Suppl 3):S986–90.PubMedCrossRef
54.
Warfield KL, Alves DA, Bradfute SB, Reed DK, VanTongeren S, Kalina WV, et al. Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol J. 2007;4:108.PubMedPubMedCentralCrossRef
55.
Warfield KL, Bradfute SB, Wells J, Lofts L, Cooper MT, Alves DA, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol. 2009;83(13):6404–15.PubMedPubMedCentralCrossRef
56.
Qiu X, Wong G, Audet J, Cutts T, Niu Y, Booth S, et al. Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus. J Virol. 2014;88(21):12703–14.PubMedPubMedCentralCrossRef
57.
Wei H, Audet J, Wong G, He S, Huang X, Cutts T, et al. Deep-sequencing of Marburg virus genome during sequential mouse passaging and cell-culture adaptation reveals extensive changes over time. Sci Rep. 2017;7(1):3390.PubMedPubMedCentralCrossRef
58.
59.
Feagins AR, Basler CF. Amino acid residue at position 79 of Marburg virus VP40 confers interferon antagonism in mouse cells. J Infect Dis. 2015;212:S219–S25.PubMedPubMedCentralCrossRef
60.
Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731–8.PubMedCrossRef
61.
Marzi A, Kercher L, Marceau J, York A, Callsion J, Gardner DJ, et al. Stat1-deficient mice are not an appropriate model for efficacy testing of recombinant vesicular stomatitis virus-based Filovirus vaccines. J Infect Dis. 2015;212(Suppl 2):S404–9.PubMedPubMedCentralCrossRef
62.
Lavender KJ, Williamson BN, Saturday G, Martellaro C, Griffin A, Hasenkrug KJ, et al. Pathogenicity of Ebola and Marburg Viruses Is Associated With Differential Activation of the Myeloid Compartment in Humanized Triple Knockout-Bone Marrow, Liver, and Thymus Mice. J Infect Dis. 2018;218(suppl_5):S409–S17.PubMedPubMedCentralCrossRef
63.
Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology. 1997;239(1):206–16.PubMedCrossRef
64.
Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect Guinea pigs and nonhuman primates. Virology. 1998;251(1):28–37.PubMedCrossRef
65.
Warfield KL, Swenson DL, Negley DL, Schmaljohn AL, Aman MJ, Bavari S. Marburg virus-like particles protect Guinea pigs from lethal Marburg virus infection. Vaccine. 2004;22(25–26):3495–502.PubMedCrossRef
66.
Hevey M, Negley D, VanderZanden L, Tammariello RF, Geisbert J, Schmaljohn C, et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine. 2001;20(3–4):586–93.PubMedCrossRef
67.
Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, Bavari S. Monovalent virus-like particle vaccine protects Guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines. 2008;7(4):417–29.PubMedCrossRef
68.
Wong G, Cao WG, He SH, Zhang ZR, Zhu WJ, Moffat E, et al. Development and characterization of a Guinea pig model for Marburg virus. Zool Res. 2018;39(1):32–41.PubMedPubMedCentralCrossRef
69.
Cross RW, Fenton KA, Geisbert JB, Ebihara H, Mire CE, Geisbert TW. Comparison of the pathogenesis of the Angola and Ravn strains of Marburg virus in the outbred Guinea pig model. J Infect Dis. 2015;212(Suppl 2):S258–70.PubMedPubMedCentralCrossRef
70.
Lofts LL, Ibrahim MS, Negley DL, Hevey MC, Schmaljohn AL. Genomic differences between Guinea pig lethal and nonlethal Marburg virus variants. J Infect Dis. 2007;196(Suppl 2):S305–12.PubMedCrossRef
71.
Atkins C, Miao J, Kalveram B, Juelich T, Smith JK, Perez D, et al. Natural History and Pathogenesis of Wild-Type Marburg Virus Infection in STAT2 Knockout Hamsters. J Infect Dis. 2018;218(suppl_5):S438–S47.PubMedPubMedCentral
72.
Zlotnik I, Simpson DI. The pathology of experimental vervet monkey disease in hamsters. Br J Exp Pathol. 1969;50(4):393–9.PubMedPubMedCentral
73.
74.
Marzi A, Banadyga L, Haddock E, Thomas T, Shen K, Horne EJ, et al. A hamster model for Marburg virus infection accurately recapitulates Marburg hemorrhagic fever. Sci Rep. 2016;6:39214.PubMedPubMedCentralCrossRef
75.
Cross RW, Mire CE, Agans KN, Borisevich V, Fenton KA, Geisbert TW. Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo). J Infect Dis. 2018;218(suppl_5):S448–S52.PubMedPubMedCentral
76.
Wong G, Zhang Z, He S, de La Vega MA, Tierney K, Soule G, et al. Marburg and Ravn Virus Infections Do Not Cause Observable Disease in Ferrets. J Infect Dis. 2018;218(suppl_5):S471–S4.PubMedPubMedCentralCrossRef
77.
Crawford LM. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. In: Food and Drug Administration H, editor. Federal Register; 2002.
78.
Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–66.PubMedCrossRef
79.
Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti JB, Kobinger GP, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014;32(43):5722–9.PubMedCrossRefPubMedCentral
80.
Tsuda Y, Safronetz D, Brown K, LaCasse R, Marzi A, Ebihara H, et al. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis. 2011;204(Suppl 3):S1090–7.PubMedPubMedCentralCrossRef
81.
Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med. 2005;11(7):786–90.PubMedCrossRef
Metadata
Title
Marburg virus pathogenesis – differences and similarities in humans and animal models
Authors
Kyle Shifflett
Andrea Marzi
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2019
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-019-1272-z

Other articles of this Issue 1/2019

Virology Journal 1/2019 Go to the issue

Case Report

Disseminated zoster in an adult patient with extensive burns: a case report

Research

The tree shrew is a promising model for the study of influenza B virus infection

Research

Phylogenetic analysis and phenotypic characterisatics of two Tibet EV-C96 strains

Research

Lamivudine therapy for chronic hepatitis B in children: a meta-analysis

Methodology

Generation of recombinant MVA-norovirus: a comparison study of bacterial artificial chromosome- and marker-based systems

Research

Multiple introductions of dengue virus strains contribute to dengue outbreaks in East Kalimantan, Indonesia, in 2015–2016

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits